COMPOUND
A synthetic peptide composed of 16 amino acids.
“Validated for multiple actions related to neurodegenerative diseases,
including cytotoxicity, neuroinflammation, and oxidative stress”
A global leader in innovative drug development
“Validated for multiple actions related to neurodegenerative diseases,
including cytotoxicity, neuroinflammation, and oxidative stress”
We are currently conducting a Phase ll clinical trial in Korea to evaluate the efficacy and safety of GV1001 in patients with Progressive Supranuclear Palsy (PSP).
Preparation are also underway for a global PSP clinical trial.
